Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-center Study to Evaluate the Safety and Tolerability of Intramuscular Administration of Alefacept (LFA-3/IgG1 Fusion Protein) in Subjects With Chronic Plaque Psoriasis Who Have Completed Studies C99-717 or C99-712

NCT00692172 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00692172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00692172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-center Study to Evaluate the Safety and Tolerability of Intramuscular Administration of Alefacept (LFA-3/IgG1 Fusion Protein) in Subjects With Chronic Plaque Psoriasis Who Have Completed Studies C99-717 or C99-712
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2001
Completion date
November 30, 2004
Enrollment
175 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis